Peptide Therapies
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
157
NCT05247528
Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 20, 2021
Completion: Oct 31, 2022
NCT06343298
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
Phase: Phase 2
Start: Nov 17, 2024
Completion: Sep 1, 2026
Loading map...